PRODUCT INFORMATION SHEET
Prolam is a short-acting benzodiazepine containing Alprazolam.
Prolam is well absorbed from the gastro-intestinal tract following oral administration, with peak plasma concentrations being achieved within 1 to 2 hours of a dose. The half-life in plasma is 12 to 15 hours. Prolam is 70 to 80% bound to plasma protein. It is metabolised in the liver primarily to alpha-hydroxyalprazolam, which is reported to be approximately half as active as the parent compound, and to an inactive benzophenone; plasma concentrations of metabolites are very low. It is excreted in urine as unchanged drug and metabolites.
USES & INDICATIONS
Prolam is given in anxeity disorders, depression, Premenstrual syndrome, phobic disorders.
ADVERSE EFFECTS AND PRECAUTIONS
Drowsiness, sedation, and ataxia are the most frequent adverse effects . They generally decrease on continued administration and are a consequence of CNS depression. Less frequent effects include vertigo, headache, confusion, mental depression, slurred speech or dysarthria , changes in libido, tremor, visual disturbances, urinary retention or incontinence, gastro-intestinal disturbances, changes in salivation, and amnesia. Precautions should be observed in patients with impaired liver function and in the elderly. Prolam should be avoided in patients with pre-existing CNS depression or coma, acute pulmonary insufficiency, or sleep apnoea.
DOSAGE & ADMINISTRATION
It is used in the treatment of anxiety disorders in doses of 0.25 to 0.5 mg three times daily by mouth, increased where necessary up to a total daily dose of 3 or 4 mg. In elderly or debilitated patients an initial dose of 0.25 mg twice or three times daily has been suggested. Doses of up to 10 mg of Prolam daily have been used in the treatment of panic attacks and depression.